Skip to main content
OpenTrials

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

114 public trials 41 recruiting studies
Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 127 locations
View Trial Details
Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT06006117

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • INSTITUT JULES BORDET - Service Hématologie Anderlecht, Belgium
  • UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie Brussels, Belgium
  • UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie Ghent, Belgium
  • CHU UCL NAMUR - SITE GODINNE - Service Hématologie Yvoir, Belgium
View all 48 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details
Recruiting

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Chronic Disease, +40 more
Locations
  • City of Hope Duarte, California, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • New York Medical College Valhalla, New York, United States
View Trial Details

Related conditions